News & Updates

Show Multimedia Only

Management of ATTR-CM with tafamidis: Challenges and opportunities

08 Dec 2021 by

The advent of tafamidis ushers in a promising new era in the treatment and management of transthyretin amyloid cardiomyopathy (ATTR-CM), with longer-term clinical data attesting to its efficacy and safety. Despite this, ATTR-CM remains an easily overlooked and potentially fatal cause of heart failure. Furthermore, its elusive diagnosis often results in late or misdiagnosis. Clinical Assistant Professor Tang Hak Chiaw, Senior Consultant with the Department of Cardiology at the National Heart Centre Singapore, speaks on the challenges and opportunities on the diagnosis and management of ATTR-CM patients while sharing his experience of using tafamidis.

Management of ATTR-CM with tafamidis: Challenges and opportunities

08 Dec 2021

Thicker subcutaneous fat during pregnancy ups pre-eclampsia risk

07 Dec 2021

Higher subcutaneous adipose tissue thickness during the second trimester, measured using ultrasound, appears to increase the risk of pre-eclampsia, a recent study has found.

Thicker subcutaneous fat during pregnancy ups pre-eclampsia risk

07 Dec 2021

Pre-eclampsia/eclampsia predicts HFpEF hospitalization

06 Dec 2021

Pre-eclampsia/eclampsia is associated with a higher risk of hospitalization due to heart failure with preserved ejection fraction (HFpEF), reveals a recent study.

Pre-eclampsia/eclampsia predicts HFpEF hospitalization

06 Dec 2021

Empagliflozin beneficial and well tolerated in acute heart failure

06 Dec 2021 by

Empagliflozin provides a significant clinical benefit within 90 days and shows no safety concerns in patients hospitalized for acute heart failure (HF), according to results of the EMPULSE trial reported at the American Heart Association (AHA) Scientific Sessions 2021.

Empagliflozin beneficial and well tolerated in acute heart failure

06 Dec 2021

Interpregnancy weight gain ups HDP risk

05 Dec 2021

Weight gain in between pregnancies worsens the risk hypertensive disorders of pregnancy (HDP), a recent study has found.

Interpregnancy weight gain ups HDP risk

05 Dec 2021

High factor H-related protein 1 expression ups ACVD risk

05 Dec 2021

Elevated expression of the factor H-related protein 1 (FHR-1) seems to be a risk factor for atherosclerotic cardiovascular disease (ACVD), a recent study has found.

High factor H-related protein 1 expression ups ACVD risk

05 Dec 2021

Canagliflozin improves HF symptoms, QoL regardless of diabetes status

04 Dec 2021 by

The SGLT2i* canagliflozin significantly improves symptoms and quality of life (QoL) early on during treatment in people with heart failure (HF) due to either reduced or preserved ejection fraction (rEF or pEF), regardless of whether they have type 2 diabetes (T2D), according to the CHIEF-HF** study presented at AHA 2021.

Canagliflozin improves HF symptoms, QoL regardless of diabetes status

04 Dec 2021

Atrial fibrillation ups in-hospital mortality in patients with acute aortic syndromes

03 Dec 2021 by

In-hospital mortality, but not stroke, is greater among patients presenting with acute aortic syndromes and atrial fibrillation (AF) than those without AF, a study has shown.

Atrial fibrillation ups in-hospital mortality in patients with acute aortic syndromes

03 Dec 2021

Olive oil intake may lower CVD risk among people with obesity

03 Dec 2021

For individuals with obesity, olive oil intake can help reduce the risk of developing cardiovascular disease (CVD) by suppressing thrombin-induced platelet activation, a study reports.

Olive oil intake may lower CVD risk among people with obesity

03 Dec 2021

Inclisiran sustains LDL-C reduction in high-risk patients with ASCVD

03 Dec 2021 by

Treatment with inclisiran consistently reduced low-density lipoprotein cholesterol (LDL-C) levels in patients with, or at high risk of, atherosclerotic cardiovascular disease (ASCVD), regardless of glycaemic status, based on a pooled analysis of the ORION-10* and ORION-11** studies presented at AHA 2021.

Inclisiran sustains LDL-C reduction in high-risk patients with ASCVD

03 Dec 2021

News & Updates

Filter by Specialty:

Specialty:

Management of ATTR-CM with tafamidis: Challenges and opportunities

Management of ATTR-CM with tafamidis: Challenges and opportunities

Thicker subcutaneous fat during pregnancy ups pre-eclampsia risk

Thicker subcutaneous fat during pregnancy ups pre-eclampsia risk

Pre-eclampsia/eclampsia predicts HFpEF hospitalization

Pre-eclampsia/eclampsia predicts HFpEF hospitalization

Empagliflozin beneficial and well tolerated in acute heart failure

Empagliflozin beneficial and well tolerated in acute heart failure

Interpregnancy weight gain ups HDP risk

Interpregnancy weight gain ups HDP risk

High factor H-related protein 1 expression ups ACVD risk

High factor H-related protein 1 expression ups ACVD risk

Canagliflozin improves HF symptoms, QoL regardless of diabetes status

Canagliflozin improves HF symptoms, QoL regardless of diabetes status

Atrial fibrillation ups in-hospital mortality in patients with acute aortic syndromes

Atrial fibrillation ups in-hospital mortality in patients with acute aortic syndromes

Olive oil intake may lower CVD risk among people with obesity

Olive oil intake may lower CVD risk among people with obesity

Inclisiran sustains LDL-C reduction in high-risk patients with ASCVD

Inclisiran sustains LDL-C reduction in high-risk patients with ASCVD